PAYS

Paysign Inc

Add to Watchlist

Advanced Chart

5.610

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.730

Open

5.610

VWAP

5.60

Vol

831.17K

Mkt Cap

305.48M

Low

5.488

Amount

4.65M

EV/EBITDA(TTM)

23.94

Total Shares

52.98M

293.72M

EV/OCF(TTM)

P/S(TTM)

4.60

Paysign, Inc. is a provider of prepaid card programs, patient affordability offerings, digital banking services and integrated payment processing designed for businesses, consumers and government institutions. The Company’s payment solutions are utilized by its corporate customers to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. It markets its prepaid card solutions under its Paysign brand. Its end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. It operates on a payments platform with fintech capabilities that can be seamlessly integrated with its clients’ systems. It offers donor engagement app, which integrates seamlessly with existing donor management systems, delivering immediate value to plasma centers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

22.58M

+21.39%

20.00M

+28.14%

20.02M

+31.22%

Estimates Revision

The market is revising Upward the revenue expectations for Paysign, Inc. (PAYS) for FY2025, with the revenue forecasts being adjusted by 7.7% over the past three months. During the same period, the stock price has changed by 90.49%.

Revenue Estimates for FY2025

Revise Upward

+7.7%

In Past 3 Month

Stock Price

Go Up

+90.49%

In Past 3 Month

6 Analyst Rating

47.77% Upside

Wall Street analysts forecast PAYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAYS is 8.29 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

47.77% Upside

Current: 5.610

Low

7.00

Averages

8.29

High

9.00

47.77% Upside

Current: 5.610

Low

7.00

Averages

8.29

High

9.00

Lake Street

Jacob Stephan

Buy

maintain

$9 -> $10

2025-08-06

Reason

Lake Street

Jacob Stephan

Price Target

$9 -> $10

2025-08-06

maintain

Buy

Reason

Lake Street analyst Jacob Stephan raised the firm's price target on Paysign to $10 from $9 and keeps a Buy rating on the shares after the company reported a beat and raise quarter. Paysign is "in the early innings of an inflection in pharma revenues," according to the analyst, who believes "investors should take note."

Barrington

Outperform

maintain

2025-06-30

Reason

Barrington

Price Target

2025-06-30

maintain

Outperform

Reason

Barrington raised the firm's price target range on Paysign to $8-$9 from a prior range of $6-$7 and keeps an Outperform rating on the shares. The firm cites the "strong outlook" for Paysign's Patient Affordability segment for the pharmaceutical industry for its target hike.

Lake Street

Jacob Stephan

Buy

maintain

$7 -> $9

2025-06-26

Reason

Lake Street

Jacob Stephan

Price Target

$7 -> $9

2025-06-26

maintain

Buy

Reason

Lake Street analyst Jacob Stephan raised the firm's price target on Paysign to $9 from $7 and keeps a Buy rating on the shares after having hosted CFO Jeff Baker for investor meetings earlier this week. The firm came away from the meetings "feeling confident" in Paysign's pharma pipeline, scalable operating model, and new plasma applications, the analyst tells investors.

DA Davidson

Peter Heckmann

Buy

maintain

$7 -> $8

2025-06-13

Reason

DA Davidson

Peter Heckmann

Price Target

$7 -> $8

2025-06-13

maintain

Buy

Reason

DA Davidson analyst Peter Heckmann raised the firm's price target on Paysign to $8 from $7 and keeps a Buy rating on the shares. Last week, Paysign announced the company had been awarded 132 established plasma donation centers through an expansion of a relationship with a major plasma collection company, and the firm believes this will increase the company's total plasma locations to 613 centers, a 27% increase over the 484 locations served at the end of Q1, the analyst tells investors in a research note.

Barrington

NULL -> Outperform

maintain

2025-05-22

Reason

Barrington

Price Target

2025-05-22

maintain

NULL -> Outperform

Reason

Barrington raised the firm's price target on Paysign to a range of $6.00-$7.00 from $5 and keeps an Outperform rating on the shares after Q1 results were better than the firm's as well as consensus expectations. Following the Q1 report, the firm is increasing its 2025 and 2026 adjusted EBITDA estimates to $16.0M and $19.1M from $12.5M and $15.3M, respectively.

DA Davidson

Peter Heckmann

Buy

maintain

$5 -> $6

2025-05-14

Reason

DA Davidson

Peter Heckmann

Price Target

$5 -> $6

2025-05-14

maintain

Buy

Reason

DA Davidson analyst Peter Heckmann raised the firm's price target on Paysign to $6 from $5 and keeps a Buy rating on the shares. The company reported impressive Q1 results, including 41% Y/Y growth in total revenue and 193% Y/Y growth in adjusted EBITDA, the analyst tells investors in a research note. The management also raised the midpoints of their prior guidance ranges for total revenue and adjusted EBITDA by 5% and 27%, respectively, the firm added.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Paysign Inc (PAYS.O) is 56.10, compared to its 5-year average forward P/E of -4.33. For a more detailed relative valuation and DCF analysis to assess Paysign Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.33

Current PE

56.10

Overvalued PE

289.07

Undervalued PE

-297.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

28.17

Current EV/EBITDA

13.94

Overvalued EV/EBITDA

55.10

Undervalued EV/EBITDA

1.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.72

Current PS

3.56

Overvalued PS

5.44

Undervalued PS

2.01